| Trial ID: | L5657 |
| Source ID: | NCT00330200
|
| Associated Drug: |
Isis 113715
|
| Title: |
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: ISIS 113715
|
| Outcome Measures: |
Primary: Evaluate the effects of ISIS 113715 on hepatic and peripheral insulin sensitivity|Examine the effect on whole body energy expenditure|Evaluate the effects on fasting and postprandial glucose excursions|Evaluate the effects on hemoglobin A1c (HbA1c) | Secondary: Expand the safety and tolerability profile for ISIS 113715|Assess the effects of ISIS 113715 on rates of basal and insulin stimulated whole body glycerol turnover|Assess the effects of ISIS 113715 on insulin suppression of local rates of lipolysis (microdialysis)
|
| Sponsor/Collaborators: |
Sponsor: Ionis Pharmaceuticals, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-11-01
|
| Completion Date: |
2007-03-01
|
| Results First Posted: |
|
| Last Update Posted: |
2022-12-05
|
| Locations: |
Yale - New Haven Hospital, New Haven, Connecticut, 06511, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00330200
|
